nature.com
Transcriptional readthrough progresses from incidental byproduct to therapeutic opportunity - Nature Structural & Molecular Biology
Several anti-cancer drugs delay transcription termination, triggering transcriptional readthrough. Readthrough has long been considered an incidental transcriptional byproduct, however a recent study ...